Zhuhai Campus of Zunyi Medical University, Zhuhai, China.
Department of Otolaryngology, Longgang Otolaryngology Hospital & Shenzhen Otolaryngology Research, Shenzhen, China.
Front Immunol. 2024 Jul 26;15:1435892. doi: 10.3389/fimmu.2024.1435892. eCollection 2024.
Allergic diseases like asthma, allergic rhinitis and dermatitis pose a significant global health burden, driving the search for novel therapies. The NLRP3 inflammasome, a key component of the innate immune system, is implicated in various inflammatory diseases. Upon exposure to allergens, NLRP3 undergoes a two-step activation process (priming and assembly) to form active inflammasomes. These inflammasomes trigger caspase-1 activation, leading to the cleavage of pro-inflammatory cytokines (IL-1β and IL-18) and GSDMD. This process induces pyroptosis and amplifies inflammation. Recent studies in humans and mice strongly suggest a link between the NLRP3 inflammasome, IL-1β, and IL-18, and the development of allergic diseases. However, further research is needed to fully understand NLRP3's specific mechanisms in allergies. This review aims to summarize the latest advances in NLRP3 activation and regulation. We will discuss small molecule drugs and natural products targeting NLRP3 as potential therapeutic strategies for allergic diseases.
过敏疾病,如哮喘、过敏性鼻炎和皮炎,给全球健康带来重大负担,促使人们寻找新的治疗方法。NLRP3 炎性小体作为先天免疫系统的关键组成部分,与各种炎症性疾病有关。在接触过敏原后,NLRP3 经历两步激活过程(预激活和组装)形成活性炎性小体。这些炎性小体触发半胱天冬酶-1 的激活,导致促炎细胞因子(IL-1β 和 IL-18)和 GSDMD 的切割。这一过程诱导细胞焦亡并放大炎症。人类和小鼠的最近研究强烈表明 NLRP3 炎性小体、IL-1β 和 IL-18 与过敏疾病的发展之间存在关联。然而,仍需要进一步研究以充分了解 NLRP3 在过敏反应中的具体机制。本综述旨在总结 NLRP3 激活和调节的最新进展。我们将讨论针对 NLRP3 的小分子药物和天然产物作为治疗过敏疾病的潜在治疗策略。
Clin Exp Med. 2024-9-26
Clin Exp Allergy. 2018-7-3
Sci Immunol. 2021-10-22
Eur Neurol. 2020
Yao Xue Xue Bao. 2016-10
J Leukoc Biol. 2020-9
Biochem Biophys Res Commun. 2019-11-15
Am J Physiol Cell Physiol. 2025-8-1
An Bras Dermatol. 2025-6-23
Psychopharmacology (Berl). 2025-4-26
Aging Dis. 2024-5-7
Cell Biochem Funct. 2024-4
Autoimmunity. 2024-12